Pharmather Holdings hoping for big things from KETARx

Executive Summary

• Pharmather Holdings provides a strategic update following the recent FDA approval of KETARx for surgical pain management, outlining a dual-track commercialization strategy and an aggressive regulatory pipeline for rare disorders.
• The company is pursuing additional FDA approvals for KETARx under the 505(b)(2) pathway, leveraging five existing orphan drug designations to seek market exclusivity and incentives, specifically targeting Complex Regional Pain Syndrome (CRPS) and other rare diseases.
• Commercialization efforts involve advanced discussions for a partnership with specialty pharmaceutical partners, with a definitive agreement targeted for Q4 2025; if no agreement is reached, the company will self-launch using established manufacturing and commercial partners.

Key Details

• Regulatory Status: KETARx has received FDA approval for surgical pain management (anesthesia and sedation for surgical and diagnostic procedures).
• Commercial Strategy:
  • Partnership Path: Advanced discussions with specialty pharmaceutical partners in pain management and injectables; definitive agreement anticipated on or before Q4 2025.
  • Self-Launch Path: If no partnership is finalized by Q4 2025, Pharmather will self-launch leveraging established manufacturing and commercial partners.
  • Distribution: Active discussions with leading and specialty drug wholesalers to supply hospitals, specialty clinics, government institutions, and clinical research entities.
• Pipeline & Regulatory Strategy:
  • Pathway: Utilizing the expedited 505(b)(2) pathway for new drug applications (NDA) based on existing data/literature to accelerate approval timelines.
  • Orphan Drug Designations: Pharmather holds five FDA orphan drug designations for ketamine:
    • Amyotrophic lateral sclerosis (approved 08/03/2021)
    • Complex Regional Pain Syndrome (approved 10/12/2021)
    • Status Epilepticus (approved 01/31/2022)
    • Ischemia/reperfusion injury during solid organ transplantation (approved 12/14/2022)
    • Rett Syndrome (approved 02/01/2023)
  • CRPS NDA:
    • Company is gathering clinical data and securing exclusive rights to support an NDA for short-term use of ketamine for CRPS.
    • CMC section supported by the recently approved KETARx.
    • Timeline: NDA submission expected by end of Q4 2025; PDUFA date targeted for Q4 2026.
    • Incentives: Qualifies for 7 years of marketing exclusivity, potential tax credits, exemption of post-approval fees, and waiver of the ~$2.4 million NDA filing fee.
  • Future NDAs: Plans to submit another NDA for a different rare disorder by Q1 2026; details to be released closer to filing.
• Strategic Focus:
  • No plans to pursue non-orphan/rare indications (e.g., depression) to avoid competition with generic ANDA holders and to secure durable market exclusivity.
  • Focus remains on rare disorders with high unmet medical need to create meaningful exclusivity and protect market share.
• Market Context:
  • Global ketamine injectable market projected to grow from $725 million (2024) to $3.42 billion (2034).
  • Annual U.S. procedures utilizing anesthesia/sedation: 50-55 million surgical and 23-24 million diagnostic procedures.
  • Company is also in initial discussions regarding potential development partnerships for ketamine-based clinical stage programs, including for Parkinson's disease.

Notable Quotes

• "With FDA approval for KETARx secured, our immediate priority is market entry, underpinned by a strong and efficient operational framework. We are also committed to broadening its therapeutic applications. Our strategy involves establishing a high-integrity ketamine franchise through a two-pronged approach: initially focusing on surgical and diagnostic anesthesia, then expanding into rare disorders leveraging ketamine's proven efficacy and safety and the FDA's increasing openness to real-world evidence and published data for drug approvals of rare disorders." — Fabio Chianelli, Founder and CEO